



Dedicated To Life

April 13, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated April 13, 2022 titled "**Zydus to supply Sagent's Caffeine Citrate Oral Solution from Jarod, post USFDA's PAS Approval**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**
(Formerly known as Cadila Healthcare Limited)

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus to supply Sagent's Caffeine Citrate Oral Solution from Jarod, post USFDA's PAS Approval

Ahmedabad, April 13, 2022

Zydus Lifesciences's (Formerly known as Cadila Healthcare Ltd.), an innovation-led global lifesciences company announced that it will be manufacturing and supplying Sagent's Caffeine Citrate Oral Solution in the strength of 60 mg per 3 mL (20 mg per mL) Single-dose Vial (US RLD: CAFKIT) from its injectables facility at Jarod, Gujarat, India. The company announced that it received the Prior Approval Supplement (PAS) Approval from the US Food and Drug Administration (USFDA), which allows for a site transfer and manufacturing of the drug at Jarod.

This product is indicated for the short-term treatment of a breathing problem (Apnea) in premature infants. Caffeine blocks certain proteins (adenosine receptors) which leads to improved breathing in these infants.

Sagent Pharmaceuticals, Inc. (Sagent), a Nichi-Iko Group Company, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing, and marketing pharmaceutical products for the North American market, with a specific emphasis on injectables.

Prior Approval Supplement (PAS)

A Prior Approval Supplement (PAS) is an application which seeks to make changes to an already approved application, such as an Abbreviated New Drug Application (ANDA), which is used by the USFDA to approve generic drugs.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878



**PRESS
RELEASE**